Implications for immunosurveillance of altered HLA class I phenotypes in human tumours - PubMed (original) (raw)
Review
Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
F Garrido et al. Immunol Today. 1997 Feb.
Abstract
HLA class I downregulation is a frequent event associated with tumour invasion and development. Altered HLA class I tumour phenotypes can have profound effects on T-cell and natural killer (NK)-cell antitumour responses. Here, Federico Garrido and colleagues analyse these altered tumour phenotypes in detail, indicating their potential relevance for implementation of immunotherapeutic protocols and strategies to overcome tumour escape mechanisms.
Similar articles
- The biological consequences of altered MHC class I expression in tumours.
Algarra I, Gaforio JJ, Cabrera T, Collado A, Garrido F. Algarra I, et al. J Biol Regul Homeost Agents. 1999 Apr-Jun;13(2):90-6. J Biol Regul Homeost Agents. 1999. PMID: 10503731 Review. - MHC class I antigens, immune surveillance, and tumor immune escape.
Garcia-Lora A, Algarra I, Garrido F. Garcia-Lora A, et al. J Cell Physiol. 2003 Jun;195(3):346-55. doi: 10.1002/jcp.10290. J Cell Physiol. 2003. PMID: 12704644 Review. - Natural history of HLA expression during tumour development.
Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. Garrido F, et al. Immunol Today. 1993 Oct;14(10):491-9. doi: 10.1016/0167-5699(93)90264-L. Immunol Today. 1993. PMID: 8274189 Review. - Loss of HLA haplotype in lung cancer cell lines: implications for immunosurveillance of altered HLA class I/II phenotypes in lung cancer.
Hiraki A, Kaneshige T, Kiura K, Ueoka H, Yamane H, Tanaka M, Harada M. Hiraki A, et al. Clin Cancer Res. 1999 Apr;5(4):933-6. Clin Cancer Res. 1999. PMID: 10213231 - MHC/HLA Class I Loss in Cancer Cells.
Garrido F. Garrido F. Adv Exp Med Biol. 2019;1151:15-78. doi: 10.1007/978-3-030-17864-2_2. Adv Exp Med Biol. 2019. PMID: 31140106 Review.
Cited by
- Tumor beta2-microglobulin and HLA-A expression is increased by immunotherapy and can predict response to CIT in association with other biomarkers.
Reis B, Attig J, Dziadek S, Graefe N, Heller A, Rieder N, Gomes B. Reis B, et al. Front Immunol. 2024 Feb 22;15:1285049. doi: 10.3389/fimmu.2024.1285049. eCollection 2024. Front Immunol. 2024. PMID: 38455061 Free PMC article. - Implication of Amyloid Precursor-like Protein 2 Expression in Cutaneous Squamous Cell Carcinoma Pathogenesis.
Huang X, Yang J, Xi H, Zhang M, Oh Y, Jin Z, Zheng Z. Huang X, et al. In Vivo. 2024 Jan-Feb;38(1):399-408. doi: 10.21873/invivo.13452. In Vivo. 2024. PMID: 38148084 Free PMC article. - Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance.
Mamat Yusof MN, Chew KT, Kampan NC, Shafiee MN. Mamat Yusof MN, et al. Int J Mol Sci. 2023 Oct 16;24(20):15233. doi: 10.3390/ijms242015233. Int J Mol Sci. 2023. PMID: 37894913 Free PMC article. Review. - Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer.
Zhao Y, Wang Z, Shi X, Liu T, Yu W, Ren X, Zhao H. Zhao Y, et al. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231202307. doi: 10.1177/15330338231202307. Technol Cancer Res Treat. 2023. PMID: 37728201 Free PMC article. - Enhancement of immune surveillance in breast cancer by targeting hypoxic tumor endothelium: Can it be an immunological switch point?
Thomas JA, Gireesh Moly AG, Xavier H, Suboj P, Ladha A, Gupta G, Singh SK, Palit P, Babykutty S. Thomas JA, et al. Front Oncol. 2023 Mar 28;13:1063051. doi: 10.3389/fonc.2023.1063051. eCollection 2023. Front Oncol. 2023. PMID: 37056346 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials